

The TB Screening Form is used to document relevant medical history and testing required. TB Services (TBS) physicians to make an appropriate diagnosis and recommendations. This documentation guide supports health care providers' responsibilities to document relevant and accurate assessment information to ensure quality referrals to TBS. Significant delays in care can arise if information is missing or unclear.



**NOTE:** Jurisdictions utilizing electronic medical record systems will be required to provide the same information.

PART 1: CLIENT COMPLETES (use ink and print clearly)					
NAME ON BC SERVICES CARD		NAME (PREFERRED)		DATE OF BIRTH (YYYY/MM/DD)	
Last	First	Middle			
FULL ADDRESS			CITY	PROVINCE	POSTAL CODE
WHAT SEX IS ON YOUR BC SERVICE CARD? <input type="checkbox"/> FEMALE <input type="checkbox"/> MALE <input type="checkbox"/> X <input type="checkbox"/> PREFER NOT TO ANSWER		DO YOU SELF-IDENTIFY AS AN INDIGENOUS PERSON? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> PREFER NOT TO ANSWER			
TO SELF-IDENTIFY YOUR GENDER AND PRONOUNS, PLEASE COMPLETE THE FOLLOWING <input type="checkbox"/> PREFER NOT TO ANSWER <input type="checkbox"/> FEMALE <input type="checkbox"/> MALE <input type="checkbox"/> AGENDER <input type="checkbox"/> NON-BINARY <input type="checkbox"/> TRANSGENDER <input type="checkbox"/> GENDER CREATIVE <input type="checkbox"/> MY GENDER IS _____ <input type="checkbox"/> MY PRONOUNS ARE _____		IF YES, HOW DO YOU IDENTIFY? SELECT ALL THAT APPLY <input type="checkbox"/> FIRST NATIONS, <input type="checkbox"/> STATUS <input type="checkbox"/> NON-STATUS <input type="checkbox"/> INUIT <input type="checkbox"/> MÉTIS DO YOU RESIDE IN A FIRST NATIONS COMMUNITY? <input type="checkbox"/> YES (50% OF TIME OR MORE) <input type="checkbox"/> NO IF YES, WHICH COMMUNITY DO YOU LIVE IN? _____			
COUNTRY OR CANADIAN PROVINCE OF BIRTH		DATE ENTERED CANADA (YYYY/MM/DD)		CELL PHONE NUMBER	
		PRIMARY PHONE NUMBER			

**1**

Trans and gender diverse clients face health inequities, some related to issues with misnaming, mispronouncing and the invisibility of this diverse population. Improvements in gender and sex data collection and management are needed. To help address these issues, the questions on this form align with [PHSA's TransCare BC program recommendations](#).

**2**

Indigenous peoples are disproportionately affected by TB due to current and historical social and health service inequities related to colonialism. Quality data is needed to inform program and service provision to close the health equity gap. Therefore it is important to ask clients culturally safe questions as outlined by the [Aboriginal Administrative Data Standards](#) and the article "[What and who is Two-Spirit?](#)".

**3**

People from countries of high TB incidence have a higher risk for exposure, and this information helps clinicians assess their TB risk and appropriate follow-up. Further, their experiences of social, legal and economic inequities in Canada affect their risk of reactivation. In BC, about 80% of active TB cases occur in [those born in high burden countries](#), although local transmission is low within BC.

PART 2: HEALTH CARE PROVIDER COMPLETES		
REASON FOR SCREENING (SEE CODES ON PAGE 2)	ALLERGIES <input type="checkbox"/> NO <input type="checkbox"/> YES, LIST ITEM AND REACTION	INJECTABLE LIVE VIRUS VACCINE OR MAJOR VIRAL ILLNESS IN THE LAST 4 WEEKS <input type="checkbox"/> YES, DATE <input type="checkbox"/> NO
IF CONTACT, NAME OF TB CASE OR ID#	LAST DATE OF CONTACT	HISTORIC EXPOSURE? IF YES, LIST DETAILS (NAME, DATE, ID#) <input type="checkbox"/> YES <input type="checkbox"/> NO

**4**

The reason for screening influences clinical interpretation, recommended follow-up tests, and whether to provide clearance. Codes are in drop-down menu on the electronic version, or on page 2 of paper version of form). **Without complete information, there will be delays in processing** (e.g., for the *pre-biologic screening* code provide the **medication name, dose and duration**. If more space is needed, use the "Additional Comments" box below).

**5**

Ensures screening tests occurred within recommended timeframe, and that reported results are valid. Contact information influences decision to recommend treatment and the type of treatment (e.g., consideration of resistance).

6 TB RISK FACTORS	<input type="checkbox"/> NONE <input type="checkbox"/> HIV <input type="checkbox"/> TRANSPLANT TYPE _____	SEE DEFINITIONS ON PAGE 2 <input type="checkbox"/> SUBSTANCE USE _____ <input type="checkbox"/> SETTING _____ <input type="checkbox"/> TRAVEL _____ <input type="checkbox"/> OTHER _____	7 TB TREATMENT RISK FACTOR HEPATITIS HISTORY <input type="checkbox"/> NONE <input type="checkbox"/> HEP B <input type="checkbox"/> HEP C <input type="checkbox"/> UNKNOWN
	<input type="checkbox"/> DIABETES <input type="checkbox"/> CHRONIC KIDNEY DISEASE/DIALYSIS <input type="checkbox"/> CANCER TYPE _____ <input type="checkbox"/> IMMUNE SUPPRESSING MEDS (INCLUDE NAME, DOSE & DURATION)		
8 TB SYMPTOMS	<input type="checkbox"/> NONE <input type="checkbox"/> CHEST PAIN <input type="checkbox"/> COUGH > 3 WEEKS <input type="checkbox"/> EXTREME FATIGUE <input type="checkbox"/> FEVER <input type="checkbox"/> BLOOD IN SPUTUM <input type="checkbox"/> LYMPHADENOPATHY <input type="checkbox"/> DRENCHING NIGHT SWEATS <input type="checkbox"/> SHORT OF BREATH <input type="checkbox"/> SPUTUM PRODUCTION <input type="checkbox"/> UNEXPLAINED WEIGHT LOSS _____ KG IN _____ MONTHS <input type="checkbox"/> OTHER _____		8
9 ADDITIONAL COMMENTS / DESCRIPTION OR CHANGE OF SYMPTOMS (E.g. new or worsening, onset, duration) / RISK FACTOR DETAILS			
10 PREVIOUS BCG <input type="checkbox"/> YES, DATE _____ <input type="checkbox"/> NO <input type="checkbox"/> UNKNOWN	BCG SCAR <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> UNKNOWN	HISTORY OF ACTIVE TB OR LTBI <input type="checkbox"/> ACTIVE <input type="checkbox"/> LATENT <input type="checkbox"/> NO	11 TREATMENT <input type="checkbox"/> YES, DATE _____ <input type="checkbox"/> NO
HISTORY OF TST <input type="checkbox"/> NO <input type="checkbox"/> YES, LOCATION/DATE _____		RESULT OF PREVIOUS TST <input type="checkbox"/> NEGATIVE <input type="checkbox"/> POSITIVE <input type="checkbox"/> UNKNOWN	
HISTORY OF IGRA <input type="checkbox"/> NO <input type="checkbox"/> YES, TYPE <input type="checkbox"/> QFT <input type="checkbox"/> T-SPOT LOCATION/DATE _____		12 RESULT OF PREVIOUS IGRA <input type="checkbox"/> NON-REACTIVE <input type="checkbox"/> REACTIVE <input type="checkbox"/> UNKNOWN	

<p><b>6</b></p> <p>Determine risk for TB exposure or TB disease. Select 'None' if no risk factors present. Note, only select immune suppressing meds if <u>currently</u> on treatment. Use drop-down menu as prompted or refer to page 2 of form for definitions.</p>	<p><b>7</b></p> <p>Hepatitis history influences TB treatment recommendations (i.e., hepatotoxicity)</p>	<p><b>8</b></p> <p>Determines if further diagnostic tests are needed. Select 'None' if asymptomatic.</p>
<p><b>9</b></p> <p>Include further relevant clinical information (e.g. recent CD4+ count, dates of symptom onset or resolution). Use separate pages if needed.</p>	<p><b>10</b></p> <p>BCG history informs TST results and/or the need for IGRA.</p>	<p><b>11</b></p> <p>If prior TB history, then TST/IGRA is not indicated.</p>
<p><b>12</b></p> <p>TB screening history is required for interpretation of results.</p>		

INITIAL TST SITE OF TST PLANT _____ GIVEN BY (PRINT) _____ HA & FACILITY _____ LOT # _____	<input type="checkbox"/> INFORMED CONSENT	<input type="checkbox"/> DID NOT TEST (REASON) _____	DATE GIVEN (YYYY/MM/DD) _____	DATE READ (YYYY/MM/DD) _____	SIZE OF INDURATION _____	READ BY (PRINT) _____
FOLLOW-UP RECOMMENDATIONS <input type="checkbox"/> NO FURTHER TESTING <input type="checkbox"/> REPEAT TST IN _____ WEEKS <input type="checkbox"/> SPUTUM FOR AFB <input type="checkbox"/> IGRA		13 <input type="checkbox"/> CXR, TYPE <input type="checkbox"/> POSTERIOR-ANTERIOR (PA) <input type="checkbox"/> LATERAL <input type="checkbox"/> DECLINED				
REPEAT TST SITE OF TST PLANT _____ GIVEN BY (PRINT) _____ HA & FACILITY _____ LOT # _____	<input type="checkbox"/> INFORMED CONSENT	<input type="checkbox"/> DID NOT TEST (REASON) _____	DATE GIVEN (YYYY/MM/DD) _____	DATE READ (YYYY/MM/DD) _____	SIZE OF INDURATION _____	READ BY (PRINT) _____
FOLLOW-UP RECOMMENDATIONS <input type="checkbox"/> NO FURTHER TESTING <input type="checkbox"/> SPUTUM FOR AFB		13 <input type="checkbox"/> CXR, TYPE <input type="checkbox"/> PA <input type="checkbox"/> LATERAL <input type="checkbox"/> DECLINED				

**13**

Please indicate what type of CXR is needed. For children less than 5 years of age and people living with HIV infection, order posterior-anterior (PA) and lateral CXR views. Order PA view only for all other clients.

**Resources:** Refer to the BCCDC [TB Manual](#), [TB DST](#), and [TST Quick Reference Guide](#). Find more TB Clinical resources at [www.bccdc.ca](http://www.bccdc.ca).

**Questions:** Refer to the documentation standards in your Health Authority. Contact the CD Leads in your region or the BCCDC TB Nurse Consultants at 604-707-5678 or email [TBNurseConsultants@bccdc.ca](mailto:TBNurseConsultants@bccdc.ca).

**References**

Grieves, Lorraine. Provincial Health Authority (PHSA) TransCare BC Program. Changing and managing gender and sex information in health information systems. Briefing note February 21, 2021. Accessed April 20, 2021.

Lönnroth K, Mor Z, Erkens C, Bruchfeld J, Nathavitharana RR, van der Werf MJ, et al. Tuberculosis in migrants in low-incidence countries: epidemiology and intervention entry points. *The International Journal of Tuberculosis and Lung Disease*. 2017;21(6):624-36.

Public Health Agency of Canada. (2018). The time is now – Chief Public Health Officer spotlight on eliminating tuberculosis in Canada. Retrieved from [www.canada.ca/en/public-health/corporate/publications/chief-public-health-officer-reports-state-public-health-canada/eliminating-tuberculosis.html](http://www.canada.ca/en/public-health/corporate/publications/chief-public-health-officer-reports-state-public-health-canada/eliminating-tuberculosis.html).

Pruden, H. and Salway, T. What and Who is Two-Spirit in Health Research?. Ottawa, ON; 2020. Retrieved from <https://cihr-irsc.gc.ca/e/52214.html>.

Truth and Reconciliation Commission of Canada. (2015). Honouring the truth, reconciling for the future: Summary of the final report of the Truth and Reconciliation Commission of Canada. Retrieved from <https://nctr.ca/records/reports/#trc-reports>.